NCT06964087
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from May 31, 2026 to May 31, 2027 Show 5 more changesShow less
- Eligibility criteria shortened, about 11 words
- Primary endpoints: details revised at 1 of 1 entry
- Start date changed from estimate of Apr 10, 2026 to Apr 23, 2026
- Secondary endpoints: details revised at 2 of 5 entries
- Study description revised
- Notable Trial status: Active, Not Recruiting to Recruiting
- Start date: May 27, 2025 to Apr 10, 2026
- Study sites: 1 to 5
- Primary completion date: May 19, 2026 to May 31, 2026
- Minor Trial status: Not Yet Recruiting to Active, Not Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in C-peptide (ng/mL)
Timeframe: 48-week
Secondary (5)
PK Parameter - Maximum Concentration (Cmax)
PK Parameter - Time to reach maximum concentration (Tmax)
PK Parameter - terminal half-life t1/2
PK Parameter - Area under the curve
Propotion of subjects with change in C-peptide greater than or equal to 0.2 ng/mL
Arms and interventions
OPT101, 1.0mg/kg, 1.5 mg/kg and 2.0 mg/kgExperimental
Part A. 6 subjects will receive 1.0mg/kg OPT101 6 subjects will receive 1.5mg/kg OPT101 6 subjects will receive 2.0mg/kg OPT101
Part B - OPT101 and Placebo to MatchExperimental
The highest tolerated dose from Part A will be tested over 48 weeks. 27 subjects (18 investigational product: 9 placebo)
Part C - OPT101 and Placebo to MatchExperimental
The highest tolerated dose in Part A will be dosed. 27 subjects (18 investigational product, 9 placebo)
Drugs: OPT101
Other: OPT101 Placebo to Match (PTM)
Sites
5 sites in 1 country